Aristides Capital’s Ginkgo Bioworks DNA Stock Holding History

Aristides Capital’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-21,300	Closed	-$209K	–	255
2024 Q4	$209K	Buy	+21,300	New	+$183K	0.04%	229

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Aristides Capital's DNA Position: Q1 2025 in Review

Aristides Capital sold out of Ginkgo Bioworks (DNA) in Q1 2025, closing a stake of 21,300 shares — an estimated $209K sold.

Aristides Capital first reported a position in DNA in Q4 2024 and held it in 1 quarter. The position peaked at $209K in Q4 2024. 167 funds tracked by Wall St. Rank hold DNA as of Q1 2025.

Aristides Capital reported no remaining Ginkgo Bioworks position as of Q1 2025 after selling out during the quarter.
Aristides Capital sold 21,300 Ginkgo Bioworks shares in Q1 2025, an estimated $209K.
Aristides Capital first reported a position in Ginkgo Bioworks in Q4 2024 and held it in 1 quarter.
Aristides Capital's Ginkgo Bioworks position peaked at $209K in Q4 2024.
167 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2025.

Based on Aristides Capital's 13F filing for Q1 2025, filed 14 May 2025.